Clinical Management of Small Cell Lung Cancer

Small cell lung cancer (SCLC) accounts for approximately 10–15 % of all lung carcinomas and is typified by rapid doubling time, early metastatic spread and an initial high sensitivity to platinum-based chemotherapy. Clinical management is stratified by disease extent into limited-stage, confined to one hemithorax with regional lymph nodes, and extensive-stage, where disease has spread beyond those boundaries. In limited-stage SCLC, concurrent platinum–etoposide chemotherapy with thoracic radiotherapy represents the standard curative-intent approach, often followed by prophylactic cranial irradiation in patients achieving complete or near-complete response. Extensive-stage disease is treated primarily with platinum–etoposide plus an immune checkpoint inhibitor targeting the programmed death-ligand 1 axis, which has extended median survival modestly in recent trials. Second-line options remain limited, with topotecan as a historical standard and novel combinations of targeted agents, immunotherapy and antiangiogenic inhibitors under investigation. Despite initial remissions, rapid emergence of drug resistance and pervasive genomic instability present major hurdles. Advances in molecular subtyping and real-time monitoring of tumour evolution promise to refine personalised therapies and improve outcomes in both early and relapsed settings.

Research from Nature Portfolio

Multiregion sequencing of sequential tumour samples during first-line platinum chemotherapy and subsequent immunotherapy has revealed that treatment induces a surge in intratumour heterogeneity and spatial clonal diversity. Early-branching clones re-emerge at relapse, implicating ancestral founder cells as the reservoir for drug-resistant subpopulations.

Targeted deep sequencing of circulating tumour DNA before and during therapy has demonstrated that clonal mutation burden in plasma correlates with progression-free and overall survival. Longitudinal ctDNA profiling uncovers enrichment of DNA-repair and NOTCH pathway mutations post-treatment, highlighting potential mechanisms of acquired resistance and offering a non-invasive tool for dynamic disease monitoring.

Clinical Management of Small Cell Lung Cancer publication trend

The graph below shows the total number of articles in clinical management of small cell lung cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Limited-stage disease: SCLC confined to one hemithorax and regional lymph nodes, amenable to combined-modality treatment.

Extensive-stage disease: SCLC that has metastasised beyond the ipsilateral thorax or involves distant organs.

Platinum–etoposide chemotherapy: A first-line regimen combining a platinum agent with etoposide to target rapidly dividing tumour cells.

Immune checkpoint inhibitor: An antibody that blocks inhibitory pathways, such as PD-1/PD-L1, to enhance antitumour immunity.

Intratumour heterogeneity: Genetic and phenotypic diversity among cancer cells within a single tumour or between lesions.

Circulating tumour DNA (ctDNA): Fragments of tumour-derived DNA in the bloodstream used for non-invasive genomic profiling and disease monitoring.

References

1. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA A Cancer Journal for Clinicians (2023).
2. Evolutionary trajectories of small cell lung cancer under therapy. Nature (2024).
3. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nature Communications (2018).
4. Emerging therapies for small cell lung cancer. Journal of Hematology & Oncology (2019).
5. Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial. Signal Transduction and Targeted Therapy (2024).
6. Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. Oncotarget (2017).
7. Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients. Scientific Reports (2015).